Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-26 @ 3:14 PM
NCT ID:
NCT07343661
Eligibility Criteria:
Inclusion Criteria:
* Informed Consent: Prior to start any study related activities, participants must be able and willing to provide written informed consent;
* Participants must have a current clinical diagnosis of asthma or EGPA;
* Physician decision to initiate treatment with mepolizumab.
* Patient has to be in treatment with medium-high dose ICS plus an additional controller in the least 6 months before screening and, if on OCS therapy, a stable dosage of prednisone (or equivalent dose of other steroids) in the 4 weeks before screening will be allowed. The above-indicated treatment has to be maintained by the patient all along the study.
* Adults aged 18 years or over.
Exclusion Criteria:
* Asthmatic patients receiving other biological treatment
* Participation in an interventional clinical trial in which the treatment regimen and/or monitoring is dictated by a protocol during the previous 12 months.
* Pregnant and breastfeeding woman
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07343661
Study Brief:
Protocol Section:
NCT07343661